Lung can­cer bio­mark­er cam­paign, launched with As­traZeneca, boosts its reach and adds phar­ma sup­port­ers

The groups are called the MET Cru­saders, the EGFR Re­sis­tors, the KRAS Kick­ers and the ROS1ders — and mem­bers are non-small cell lung can­cer pa­tients who share the same bio­mark­ers. The groups, though, are al­so avid can­cer bio­mark­er test­ing ad­vo­cates and sup­port­ers of LUNGevi­ty’s “No One Missed” cam­paign to en­cour­age com­pre­hen­sive test­ing in lung can­cer.

LUNGevi­ty launched the cam­paign with the back­ing of co-found­ing part­ner As­traZeneca more than two years ago, but now in­cludes more than a dozen oth­er sup­port­ing phar­mas such as Am­gen, Bay­er, Sanofi, Dai­ichi-Sankyo, Genen­tech, Mer­ck, Re­gen­eron, Eli Lil­ly, No­var­tis and Take­da.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER